| 1 | Recent advances in small-molecular therapeutics for COVID-19显示文摘The COVID-19 pandemic poses a fundamental challenge to global health.Since the outbreak of SARS-CoV-2,great efforts have been made to identify antiviral strategies and develop therapeutic drugs to combat the disease.There are different strategies for developing small molecular anti-SARS-CoV-2 drugs,including targeting coronavirus structural proteins(e.g.spike protein),non-structural proteins(nsp)(e.g.RdRp,Mpro,PLpro,helicase,nsp14,and nsp16),host proteases(e.g.TMPRSS2,cathepsin,and furin)and the pivotal proteins mediating endocytosis(e.g.PIKfyve),as well as developing endosome acidification agents and immune response modulators.Favipiravir and chloroquine are the anti-SARS-CoV-2 agents that were identified earlier in this epidemic and repurposed for COVID-19 clinical therapy based on these strategies.However,their efficacies are controversial.Currently,three small molecular anti-SARSCoV-2 agents,remdesivir,molnupiravir,and Paxlovid(PF-07321332 plus ritonavir),have been granted emergency use authorization or approved for COVID-19 therapy in many countries due to their significant curative effects in phase Ⅲ trials.Meanwhile,a large number of promising anti-SARS-CoV-2 drug candidates have entered clinical evaluation.The development of these drugs brings hope for us to finally conquer COVID-19.In this account,we conducted a comprehensive review of the recent advances in small molecule anti-SARS-CoV-2 agents according to the target classification.Here we present all the approved drugs and most of the important drug candidates for each target,and discuss the challenges and perspectives for the future research and development of anti-SARS-CoV-2 drugs. | Lei Zhong Zhipeng Zhao Xuerun Peng Jun Zou Shengyong Yang | 2022 | Precision Clinical Medicine2022，5，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员